Xencor Inc
$ 12.51
3.65%
14 Apr - close price
- Market Cap 885,197,000 USD
- Current Price $ 12.51
- High / Low $ 12.65 / 12.04
- Stock P/E N/A
- Book Value 8.84
- EPS -1.24
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.14 %
- 52 Week High 18.69
- 52 Week Low 6.92
About
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
Analyst Target Price
$28.42
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-25 | 2024-11-05 | 2024-08-05 | 2024-05-09 | 2024-02-27 | 2023-11-07 | 2023-08-03 | 2023-05-08 |
| Reported EPS | -0.09 | -0.08 | -0.41 | -0.66 | -0.62 | -0.71 | -1.07 | -1.11 | -0.31 | -0.4 | -0.37 | -1.02 |
| Estimated EPS | -0.6037 | -0.69 | -0.72 | -0.581 | -0.7862 | -0.98 | -0.88 | -0.79 | -0.09 | -0.73 | -0.8 | -0.66 |
| Surprise | 0.5137 | 0.61 | 0.31 | -0.079 | 0.1662 | 0.27 | -0.19 | -0.32 | -0.22 | 0.33 | 0.43 | -0.36 |
| Surprise Percentage | 85.0919% | 88.4058% | 43.0556% | -13.5972% | 21.1397% | 27.551% | -21.5909% | -40.5063% | -244.4444% | 45.2055% | 53.75% | -54.5455% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.65 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XNCR
2026-04-13 19:39:27
Xencor Inc.'s Senior Vice President and CFO, Bart Jan Cornelissen, sold 3,499 shares of common stock on April 10, 2026, at an average price of $12.2865 per share. This transaction was specifically to cover withholding taxes upon the vesting of 14,088 restricted stock units, and not an open-market sale. After the sale, Cornelissen directly held 75,898 shares of Xencor common stock.
2026-04-13 13:48:00
This article analyzes Xencor Inc. (NASDAQ: XNCR) stock movements, highlighting a weak near-term sentiment that could precede shifts in mid and long-term outlook. It identifies an exceptional 97.3:1 risk-reward setup targeting a 25.6% gain versus 0.3% risk. The piece also outlines specific AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
2026-04-10 19:10:09
This SEC Form 144 filing from Xencor Inc. (XNCR) indicates the proposed sale of 3,499 shares of common stock resulting from restricted stock vesting on April 9, 2026. The filing also documents a prior sale of 2,517 shares on March 5, 2026, by Bart Jan Cornelissen. The total aggregate market value of the shares to be sold is $42,990.46.
2026-04-04 19:11:24
Xencor, Inc. (NASDAQ:XNCR) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $24.38. Despite beating Q4 EPS estimates, the company's revenue fell 46.6% year-over-year, and it remains unprofitable. Insider activity shows recent sales by the CEO and a VP, totaling approximately $499,817 over the past 90 days.
2026-04-03 07:40:32
Xencor's Sr. Vice President & CSO, John R Desjarlais, sold 2,663 shares of common stock for $31,676. This transaction occurred on March 3, 2026, alongside acquisitions of restricted stock units and options. The company is also managing a royalty dispute with Alexion Pharmaceuticals and received a reiterated Buy rating from Truist Securities.
2026-04-02 07:40:42
Celia Eckert, SVP and General Counsel of Xencor Inc. (NASDAQ: XNCR), sold 1,492 shares for a total of $17,747. This sale occurred after acquiring 18,680 shares for $0 and being granted options for 112,080 shares with a vesting schedule. The company is noted as undervalued by InvestingPro, holding more cash than debt but also burning through cash rapidly.
